These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33922418)

  • 1. Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.
    Park GT; Yoon JW; Yoo SB; Song YC; Song P; Kim HK; Han J; Bae SJ; Ha KT; Mishchenko NP; Fedoreyev SA; Stonik VA; Kim MB; Kim JH
    Mar Drugs; 2021 Apr; 19(5):. PubMed ID: 33922418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.
    Park GT; Kwon YW; Lee TW; Kwon SG; Ko HC; Kim MB; Kim JH
    Front Immunol; 2019; 10():2095. PubMed ID: 31552041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withaferin A attenuates bleomycin-induced scleroderma by targeting FoxO3a and NF-κβ signaling: Connecting fibrosis and inflammation.
    Bale S; Pulivendala G; Godugu C
    Biofactors; 2018 Nov; 44(6):507-517. PubMed ID: 30367690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleroderma-like Impairment in the Network of Telocytes/CD34
    Rosa I; Romano E; Fioretto BS; Guasti D; Ibba-Manneschi L; Matucci-Cerinic M; Manetti M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
    Ohashi T; Yamamoto T
    Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models.
    Zhang Z; Wu Y; Wu B; Qi Q; Li H; Lu H; Fan C; Feng C; Zuo J; Niu L; Tang W
    Arthritis Res Ther; 2019 Dec; 21(1):290. PubMed ID: 31842999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
    Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities.
    Peng B; Hu Q; He R; Hou H; Lian D; Chen Y; Li H; Song L; Gao Y; Chen T; Zhang G; Li J
    BMC Complement Med Ther; 2023 Feb; 23(1):62. PubMed ID: 36810081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma.
    Koca SS; Ozgen M; Dagli AF; Gozel N; Ozercan IH; Isik A
    Adv Clin Exp Med; 2016; 25(2):249-53. PubMed ID: 27627557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma.
    Yang L; Serada S; Fujimoto M; Terao M; Kotobuki Y; Kitaba S; Matsui S; Kudo A; Naka T; Murota H; Katayama I
    PLoS One; 2012; 7(7):e41994. PubMed ID: 22911870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypical analysis of myofibroblasts and mesenchymal cells in the bleomycin-induced rat scleroderma, with particular reference to their origin.
    Juniantito V; Izawa T; Yuasa T; Ichikawa C; Tanaka M; Kuwamura M; Yamate J
    Exp Toxicol Pathol; 2013 Jul; 65(5):567-77. PubMed ID: 22749686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
    Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid cell populations and fibrogenic parameters in bleomycin- and HOCl-induced fibrosis.
    Raker VK; Ook KY; Haub J; Lorenz N; Schmidt T; Stegemann A; Böhm M; Schuppan D; Steinbrink K
    Exp Dermatol; 2016 Nov; 25(11):887-894. PubMed ID: 27307019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma.
    Yamamoto T; Nishioka K
    Clin Immunol; 2002 Jan; 102(1):77-83. PubMed ID: 11781070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective.
    Yamamoto T; Nishioka K
    Exp Dermatol; 2005 Feb; 14(2):81-95. PubMed ID: 15679577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
    Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
    Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental Mouse Model of Bleomycin-Induced Skin Fibrosis.
    Błyszczuk P; Kozlova A; Guo Z; Kania G; Distler O
    Curr Protoc Immunol; 2019 Sep; 126(1):e88. PubMed ID: 31483105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrogenic effects of C-C chemokine receptor type 2 antagonist in a bleomycin-induced scleroderma model.
    Ishikawa M; Yamamoto T
    Exp Dermatol; 2021 Jan; 30(1):179-184. PubMed ID: 32096250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.